This dataset reports the uptake of at least one dose of the COVID-19 vaccine among patients registered with GP practices in England. It provides a measure of immunisation coverage and supports monitoring of public health efforts to reduce the spread and severity of COVID-19. The data is sourced from Immform, EMIS Health, and TPP systems.

Rationale

Vaccination is a critical tool in controlling the COVID-19 pandemic. Monitoring vaccine uptake helps identify gaps in coverage, inform targeted outreach, and evaluate the effectiveness of immunisation campaigns. This indicator supports efforts to increase vaccine uptake and protect vulnerable populations.

Numerator

The numerator is the number of patients who have received at least one dose of a COVID-19 vaccine.

Denominator

The denominator is the total number of patients registered with GP practices, as recorded in the Immform-EMIS Health and TPP systems.

Caveats

Automated data collection is only possible from GP practices whose IT suppliers support automatic extraction. Some organisations may not have responded or submitted data, which could affect completeness and accuracy.

External References

More information is available from the following source:

Immform COVID-19 Collections Portal

Localities ExplainedThis dataset contains data based on either the resident locality or registered locality of the patient, a distinction is made between resident locality and registered locality populations:Resident Locality refers to individuals who live within the defined geographic boundaries of the locality. These boundaries are aligned with official administrative areas such as wards and Lower Layer Super Output Areas (LSOAs).Registered Locality refers to individuals who are registered with GP practices that are assigned to a locality based on the Primary Care Network (PCN) they belong to. These assignments are approximate—PCNs are mapped to a locality based on the location of most of their GP surgeries. As a result, locality-registered patients may live outside the locality, sometimes even in different towns or cities.This distinction is important because some health indicators are only available at GP practice level, without information on where patients actually reside. In such cases, data is attributed to the locality based on GP registration, not residential address.

Click here to explore more from the Birmingham and Solihull Integrated Care Partnerships Outcome Framework.

PIONEER: The impact of ethnicity and multi-morbidity on COVID-related outcomes; a primary care supplemented hospitalised dataset Dataset number 3.0

Coronavirus disease 2019 (COVID-19) was identified in January 2020. Currently, there have been more than 65million cases and more than 1.5 million deaths worldwide. Some individuals experience severe manifestations of infection, including viral pneumonia, adult respiratory distress syndrome (ARDS) and death. Evidence suggests that older patients, those from some ethnic minority groups and those with multiple long-term health conditions have worse outcomes. This secondary care COVID dataset contains granular demographic and morbidity data, supplemented from primary care records, to add to the understanding of patient factors on disease outcomes.

PIONEER geography The West Midlands (WM) has a population of 5.9 million & includes a diverse ethnic & socio-economic mix. There is a higher than average percentage of minority ethnic groups. WM has a large number of elderly residents but is the youngest population in the UK. Each day >100,000 people are treated in hospital, see their GP or are cared for by the NHS. The West Midlands was one of the hardest hit regions for COVID admissions in both wave 1 and 2.

EHR. University Hospitals Birmingham NHS Foundation Trust (UHB) is one of the largest NHS Trusts in England, providing direct acute services & specialist care across four hospital sites, with 2.2 million patient episodes per year, 2750 beds & 100 ITU beds. UHB runs a fully electronic healthcare record (EHR) (PICS; Birmingham Systems), a shared primary & secondary care record (Your Care Connected) & a patient portal “My Health”. UHB has cared for >5000 COVID admissions to date.

Scope: All COVID swab confirmed hospitalised patients to UHB from January – May 2020. The dataset includes highly granular patient demographics & co-morbidities taken from ICD-10 & SNOMED-CT codes but also primary care records and clinic letters. Serial, structured data pertaining to care process (timings, staff grades, specialty review, wards), presenting complaint, acuity, all physiology readings (pulse, blood pressure, respiratory rate, oxygen saturations), all blood results, microbiology, all prescribed & administered treatments (fluids, antibiotics, inotropes, vasopressors, organ support), all outcomes. Linked images available (radiographs, CT, MRI, ultrasound).

Available supplementary data: Health data preceding and following admission event. Matched “non-COVID” controls; ambulance, 111, 999 data, synthetic data.

Available supplementary support: Analytics, Model build, validation & refinement; A.I.; Data partner support for ETL (extract, transform & load) process, Clinical expertise, Patient & end-user access, Purchaser access, Regulatory requirements, Data-driven trials, “fast screen” services.

Tuberculosis (TB) is caused by a bacterium called Mycobacterium tuberculosis.  TB remains a significant global health problem. The UK has one of the highest rates of TB in Europe, with almost 5000 new cases notified in 2019. Within the UK, Birmingham and the West Midlands are particular hotspots for TB, with over 300 cases of active disease and approximately 10 times that of new latent infections diagnosed each year.

Birmingham and the West Midlands have experienced particularly high rates of COVID-19 during the pandemic and there is increasing evidence that individuals of Black, Asian and minority ethnicities (BAME) experience the most significant morbidity and highest mortality rates due to COVID-19. These groups also experience the highest burdens of TB, both in the UK and overseas.

Epidemiological data suggests that current and previous tuberculosis (TB) increase the risk of COVID-19 mortality and severe disease. There is also evidence of immunopathogenic overlap between the two infections with in vitro studies finding that SARS-CoV-2 infection is increased in human macrophages cultured in the inflammatory milieu of TB-infected macrophages.

This dataset would enable a deeper analysis of demography and clinical outcomes associated with COVID-19 in patients with concurrent TB.

PIONEER geography: the West Midlands (WM) has a population of 5.9 million & includes a diverse ethnic & socio-economic mix.

EHR. UHB is one of the largest NHS Trusts in England, providing direct acute services & specialist care across four hospital sites, with 2.2 million patient episodes per year, 2750 beds & an expanded 250 ITU bed capacity during COVID. UHB runs a fully electronic healthcare record (EHR) (PICS; Birmingham Systems), a shared primary & secondary care record (Your Care Connected) & a patient portal “My Health”.

Scope: All hospitalised patients admitted to UHB during the COVID-19 pandemic, curated to focus on Mycobacterium tuberculosis and SARS-CoV-2. Longitudinal & individually linked, so that the preceding & subsequent health journey can be mapped & healthcare utilisation prior to & after admission understood. The dataset includes highly granular patient demographics & co-morbidities taken from ICD-10 & SNOMED-CT codes. Serial, structured data pertaining to acute care process (A&E, triage, IP, ITU admissions), presenting complaint, DNAR teal, all physiology readings (AVPU scale, Covid CFS, blood pressure, respiratory rate, oxygen saturations and others), all blood results, imaging reports, all prescribed & administered treatments, all outcomes.

Available supplementary data: Matched controls; ambulance, OMOP data, synthetic data.

Available supplementary support: Analytics, Model build, validation & refinement; A.I.; Data partner support for ETL (extract, transform & load) process, Clinical expertise, Patient & end-user access, Purchaser access, Regulatory requirements, Data-driven trials, “fast screen” services.

PIONEER: Deeply-phenotyped hospital COVID patients: severity, acuity, therapies, outcomes Dataset number 4.0

Coronavirus disease 2019 (COVID-19) was identified in January 2020. Currently, there have been more than 6 million cases& more than 1.5 million deaths worldwide. Some individuals experience severe manifestations of infection, including viral pneumonia, adult respiratory distress syndrome (ARDS)& death. There is a pressing need for tools to stratify patients, to identify those at greatest risk. Acuity scores are composite scores which help identify patients who are more unwell to support & prioritise clinical care. There are no validated acuity scores for COVID-19 & it is unclear whether standard tools are accurate enough to provide this support. This secondary care COVID dataset contains granular demographic, morbidity, serial acuity and outcome data to inform risk prediction tools in COVID-19.

PIONEER geography The West Midlands (WM) has a population of 5.9 million & includes a diverse ethnic & socio-economic mix. There is a higher than average percentage of minority ethnic groups. WM has a large number of elderly residents but is the youngest population in the UK. Each day >100,000 people are treated in hospital, see their GP or are cared for by the NHS. The West Midlands was one of the hardest hit regions for COVID admissions in both wave 1 & 2.

EHR. University Hospitals Birmingham NHS Foundation Trust (UHB) is one of the largest NHS Trusts in England, providing direct acute services & specialist care across four hospital sites, with 2.2 million patient episodes per year, 2750 beds & 100 ITU beds. UHB runs a fully electronic healthcare record (EHR) (PICS; Birmingham Systems), a shared primary & secondary care record (Your Care Connected) & a patient portal “My Health”. UHB has cared for >5000 COVID admissions to date.

Scope: All COVID swab confirmed hospitalised patients to UHB from January – May 2020. The dataset includes highly granular patient demographics & co-morbidities taken from ICD-10 & SNOMED-CT codes but also primary care records& clinic letters. Serial, structured data pertaining to care process (timings, staff grades, specialty review, wards), presenting complaint, acuity, all physiology readings (pulse, blood pressure, respiratory rate, oxygen saturations), all blood results, microbiology, all prescribed & administered treatments (fluids, antibiotics, inotropes, vasopressors, organ support), all outcomes. Linked images available (radiographs, CT, MRI, ultrasound).

Available supplementary data: Health data preceding & following admission event. Matched “non-COVID” controls; ambulance, 111, 999 data, synthetic data.

Available supplementary support: Analytics, Model build, validation & refinement; A.I.; Data partner support for ETL (extract, transform & load) process, Clinical expertise, Patient & end-user access, Purchaser access, Regulatory requirements, Data-driven trials, “fast screen” services.

This indicator is designed to accompany the SHMI publication. The SHMI includes all deaths reported of patients who were admitted to non-specialist acute trusts in England and either died while in hospital or within 30 days of discharge. Deaths related to COVID-19 are excluded from the SHMI. A contextual indicator on the percentage of deaths reported in the SHMI which occurred in hospital and the percentage which occurred outside of hospital is produced to support the interpretation of the SHMI. Notes: 1. As of the July 2020 publication, COVID-19 activity has been excluded from the SHMI. The SHMI is not designed for this type of pandemic activity and the statistical modelling used to calculate the SHMI may not be as robust if such activity were included. Activity that is being coded as COVID-19, and therefore excluded, is monitored in the contextual indicator 'Percentage of provider spells with COVID-19 coding' which is part of this publication. 2. Please note that there was a fall in the overall number of spells for England from March 2020 due to COVID-19 impacting on activity for England and the number has not returned to pre-pandemic levels. Further information at Trust level is available in the contextual indicator ‘Provider spells compared to the pre-pandemic period’ which is part of this publication. 3. There is a shortfall in the number of records for Chelsea and Westminster Hospital NHS Foundation Trust (trust code RQM). Values for this trust are based on incomplete data and should therefore be interpreted with caution. 4. Frimley Health NHS Foundation Trust (trust code RDU) stopped submitting data to the Secondary Uses Service (SUS) during June 2022 and did not start submitting data again until April 2023 due to an issue with their patient records system. This is causing a large shortfall in records and values for this trust should be viewed in the context of this issue. 5. Barts Health NHS Trust (trust code R1H), Cambridge University Hospitals NHS Foundation Trust (trust code RGT), Croydon Health Services NHS Trust (trust code RJ6), East and North Hertfordshire NHS Trust (trust code RWH), Epsom and St Helier University Hospitals NHS Trust (trust code RVR), Frimley Health NHS Foundation Trust (trust code RDU), Imperial College Healthcare NHS Trust (trust code RYJ), Manchester University NHS Foundation Trust (trust code R0A), Norfolk and Norwich University Hospitals NHS Foundation Trust (trust code RM1), Sandwell and West Birmingham Hospitals NHS Trust (trust code RXK), and University Hospitals of Derby and Burton NHS Foundation Trust (trust code RTG) are now submitting Same Day Emergency Care (SDEC) data to the Emergency Care Data Set (ECDS) rather than the Admitted Patient Care (APC) dataset. The SHMI is calculated using APC data. Removal of SDEC activity from the APC data may impact a trust’s SHMI value and may increase it. More information is available in the Background Quality Report. 6. On 1 July 2023 Southport and Ormskirk Hospital NHS Trust (trust code RVY) was acquired by St Helens and Knowsley Teaching Hospitals NHS Trust (trust code RBN). The new organisation is known as Mersey and West Lancashire Teaching Hospitals NHS Trust (trust code RBN). This new organisation structure is reflected from this publication onwards. 7. Further information on data quality can be found in the SHMI background quality report, which can be downloaded from the 'Resources' section of the publication page.

Background: Coronavirus disease 2019 (COVID-19) was identified in January 2020. Currently, there have been more than 125 million cases, and more than 2.7 million deaths worldwide. Some individuals experience severe manifestations of infection, including viral pneumonitis, adult respiratory distress syndrome (ARDS) and death. Many patients required ventilatory support including high flow oxygen, continuous positive airway pressure and intubated with or without tracheotomy. There was considerable learning on how to manage COVID-19 during the pandemic and new drugs became available during the different waves. This secondary care COVID dataset contains granular ventilatory, demographic, morbidity, serial acuity, medications and outcome data in COVID-19 across all waves and will be continuously refreshed.

PIONEER geography: The West Midlands (WM) has a population of 5.9 million and includes a diverse ethnic and socio-economic mix. There is a higher than average percentage of minority ethnic groups. WM has a large number of elderly residents but is the youngest population in the UK. Each day, more than 100,000 people are treated in hospital, see their GP or are cared for by the NHS. The West Midlands was one of the hardest hit regions for COVID admissions across all waves.

Electronic Health Records (EHR): University Hospitals Birmingham NHS Foundation Trust (UHB) is one of the largest NHS Trusts in England, providing direct acute services and specialist care across four hospital sites, with 2.2 million patient episodes per year, 2750 beds and 100 ITU beds. ITU capacity increased to 250 beds during the COVID pandemic. UHB runs a fully electronic healthcare record (EHR) (PICS; Birmingham Systems), a shared primary and secondary care record (Your Care Connected) and a patient portal “My Health”. UHB has cared for more than 10,000 COVID admissions to date.

Scope: All COVID swab confirmed hospitalised patients to UHB from January 2020 to the current date. The dataset includes highly granular patient demographics and co-morbidities taken from ICD-10 and SNOMED-CT codes. Serial, structured data pertaining to care process (timings, staff grades, specialty review, wards), severity, ventilatory requirements, acuity, all physiology readings (pulse, blood pressure, respiratory rate, oxygen saturations), all blood results, microbiology, all prescribed and administered treatments (fluids, antibiotics, inotropes, vasopressors, organ support, dexamethasone, remdesivir, tocilizumab), all outcomes.

Available supplementary data: Ambulance, 111, 999 data, synthetic data.

Available supplementary support: Analytics, Model build, validation and refinement; A.I.; Data partner support for ETL (extract, transform and load) process, Clinical expertise, Patient and end-user access, Purchaser access, Regulatory requirements, Data-driven trials, “fast screen” services.

All chlamydia diagnoses among people accessing sexual health services* in England who are also residents in England, expressed as a rate per 100,000 population. Data is presented by area of patient residence and include those residents in England and those with an unknown residence (data for those residents outside of England is not included).*Sexual health services providing STI related care (Levels 1, 2 or 3). Further details on the levels of sexual healthcare provision are provided in the https://www.bashh.org/about-bashh/publications/standards-for-the-management-of-stis/ .RationaleChlamydia causes avoidable sexual and reproductive ill-health. While chlamydial infections are more commonly found among young adults aged under 25 years, women and men aged 25 years and over are also at-risk of chlamydia.Definition of numeratorThe number of chlamydia diagnoses among people accessing sexual health services in England. Includes those diagnosed through NHS and local authority commissioned testing and excludes those diagnosed through private testing.Chlamydia data is sourced from GUMCAD STI Surveillance System (Level 3) and CTAD Chlamydia Surveillance System (Levels 1 and 2), UKHSA. GUMCAD data is reported by SHSs providing STI related care (Levels 2 or 3). CTAD is reported by laboratories conducting testing for any service (Levels 1, 2 or 3) providing chlamydia testing.A maximum of one chlamydia test or diagnosis per individual is counted within a 6 week period. Any further tests or diagnoses within the 6 week period are not counted. Diagnoses are kept in preference over negative results during this process. Patients cannot be tracked between clinics and therefore de-duplication relies on patient consultations at a single service.The clinical definition used to diagnose chlamydia is given at https://www.bashh.org/guidelines .Definition of denominatorThe denominators for 2012 to 2022 are sourced from Office for National Statistics (ONS) population estimates based on the 2021 Census.Population estimates for 2023 were not available at the time of publication – therefore rates for 2023 are calculated using estimates from 2022 as a proxy.Further details on the ONS census are available from the https://www.ons.gov.uk/census .CaveatsEvery effort is made to ensure accuracy and completeness of GUMCAD data, including web-based reporting with integrated checks on data quality. However, responsibility for the accuracy and completeness of data lies with the reporting service.Data is updated on an annual basis due to clinic or laboratory resubmissions and improvements to data cleaning. Data may differ from previous publications.Figures reported in 2020 and 2021 are notably lower than previous years due to the disruption to SHSs during the national response to the COVID-19 pandemic.

OMOP dataset: Hospital COVID patients: severity, acuity, therapies, outcomes Dataset number 2.0

Coronavirus disease 2019 (COVID-19) was identified in January 2020. Currently, there have been more than 6 million cases & more than 1.5 million deaths worldwide. Some individuals experience severe manifestations of infection, including viral pneumonia, adult respiratory distress syndrome (ARDS) & death. There is a pressing need for tools to stratify patients, to identify those at greatest risk. Acuity scores are composite scores which help identify patients who are more unwell to support & prioritise clinical care. There are no validated acuity scores for COVID-19 & it is unclear whether standard tools are accurate enough to provide this support. This secondary care COVID OMOP dataset contains granular demographic, morbidity, serial acuity and outcome data to inform risk prediction tools in COVID-19.

PIONEER geography The West Midlands (WM) has a population of 5.9 million & includes a diverse ethnic & socio-economic mix. There is a higher than average percentage of minority ethnic groups. WM has a large number of elderly residents but is the youngest population in the UK. Each day >100,000 people are treated in hospital, see their GP or are cared for by the NHS. The West Midlands was one of the hardest hit regions for COVID admissions in both wave 1 & 2.

EHR. University Hospitals Birmingham NHS Foundation Trust (UHB) is one of the largest NHS Trusts in England, providing direct acute services & specialist care across four hospital sites, with 2.2 million patient episodes per year, 2750 beds & 100 ITU beds. UHB runs a fully electronic healthcare record (EHR) (PICS; Birmingham Systems), a shared primary & secondary care record (Your Care Connected) & a patient portal “My Health”. UHB has cared for >5000 COVID admissions to date. This is a subset of data in OMOP format.

Scope: All COVID swab confirmed hospitalised patients to UHB from January – August 2020. The dataset includes highly granular patient demographics & co-morbidities taken from ICD-10 & SNOMED-CT codes. Serial, structured data pertaining to care process (timings, staff grades, specialty review, wards), presenting complaint, acuity, all physiology readings (pulse, blood pressure, respiratory rate, oxygen saturations), all blood results, microbiology, all prescribed & administered treatments (fluids, antibiotics, inotropes, vasopressors, organ support), all outcomes.

Available supplementary data: Health data preceding & following admission event. Matched “non-COVID” controls; ambulance, 111, 999 data, synthetic data. Further OMOP data available as an additional service.

Available supplementary support: Analytics, Model build, validation & refinement; A.I.; Data partner support for ETL (extract, transform & load) process, Clinical expertise, Patient & end-user access, Purchaser access, Regulatory requirements, Data-driven trials, “fast screen” services.

The CONTRAST study explored how the Covid-19 (lockdown) restrictions affected lives of older children in the UK, particularly how they have influenced learning, eating, physical and other activities and wellbeing.

DECOVID, a multi-centre research consortium, was founded in March 2020 by two United Kingdom (UK) National Health Service (NHS) Foundation Trusts (comprising three acute care hospitals) and three research institutes/universities: University Hospitals Birmingham (UHB), University College London Hospitals (UCLH), University of Birmingham, University College London and The Alan Turing Institute. The original aim of DECOVID was to share harmonised electronic health record (EHR) data from UCLH and UHB to enable researchers affiliated with the DECOVID consortium to answer clinical questions to support the COVID-19 response.   ​​   ​​The DECOVID database has now been placed within the infrastructure of PIONEER, a Health Data Research (HDR) UK funded data hub that contains data from acute care providers, to make the DECOVID database accessible to external researchers not affiliated with the DECOVID consortium.  

This highly granular dataset contains 256,804 spells and 165,414 hospitalised patients. The data includes demographics, serial physiological measurements, laboratory test results, medications, procedures, drugs, mortality and readmission.

Geography: UHB is one of the largest NHS Trusts in England, providing direct acute services & specialist care across four hospital sites, with 2.2 million patient episodes per year, 2750 beds & > 120 ITU bed capacity. UCLH provides first-class acute and specialist services in six hospitals in central London, seeing more than 1 million outpatient and 100,000 admissions per year. Both UHB and UCLH have fully electronic health records. Data has been harmonised using the OMOP data model. Data set availability: Data access is available via the PIONEER Hub for projects which will benefit the public or patients. This can be by developing a new understanding of disease, by providing insights into how to improve care, or by developing new models, tools, treatments, or care processes. Data access can be provided to NHS, academic, commercial, policy and third sector organisations. Applications from SMEs are welcome. There is a single data access process, with public oversight provided by our public review committee, the Data Trust Committee. Contact pioneer@uhb.nhs.uk or visit www.pioneerdatahub.co.uk for more details.

Available supplementary data: Matched controls; ambulance and community data. Unstructured data (images). We can provide the dataset in other common data models and can build synthetic data to meet bespoke requirements.

Available supplementary support: Analytics, model build, validation & refinement; A.I. support. Data partner support for ETL (extract, transform & load) processes. Bespoke and “off the shelf” Trusted Research Environment (TRE) build and run. Consultancy with clinical, patient & end-user and purchaser access/ support. Support for regulatory requirements. Cohort discovery. Data-driven trials and “fast screen” services to assess population size.

All diagnoses of first episode genital herpes among people accessing sexual health services* in England who are also residents in England, expressed as a rate per 100,000 population. Data is presented by area of patient residence and include those residents in England and those with an unknown residence (data for those residents outside of England is not included).*Sexual health services providing STI related care (Levels 2 and 3). Further details on the levels of sexual healthcare provision are provided in the https://www.bashh.org/about-bashh/publications/standards-for-the-management-of-stis/ .RationaleGenital herpes is the most common ulcerative sexually transmitted infection seen in England. Infections are frequently due to herpes simplex virus (HSV) type 2, although HSV-1 infection is also seen. Recurrent infections are common with patients returning for treatment.Definition of numeratorThe number of diagnoses of genital herpes (first episode) among people accessing sexual health services in England who are also residents in England.Episode Activity codes (SNOMED or Sexual Health and HIV Activity Property Types (SHHAPT)) relating to diagnosis of genital herpes (first episode) were used. The clinical criteria used to diagnose the conditions are given at https://www.bashh.org/guidelines .Data was de-duplicated to ensure that a patient received a diagnostic code only once for each episode. Patients cannot be tracked between services and therefore de-duplication relies on patient consultations at a single service.Definition of denominatorThe denominators for 2012 to 2022 are sourced from Office for National Statistics (ONS) population estimates based on the 2021 Census.Population estimates for 2023 were not available at the time of publication – therefore rates for 2023 are calculated using estimates from 2022 as a proxy.Further details on the ONS census are available from the https://www.ons.gov.uk/census .CaveatsEvery effort is made to ensure accuracy and completeness of GUMCAD data, including web-based reporting with integrated checks on data quality. However, responsibility for the accuracy and completeness of data lies with the reporting service.Data is updated on an annual basis due to clinic or laboratory resubmissions and improvements to data cleaning. Data may differ from previous publications.Figures reported in 2020 and 2021 are notably lower than previous years due to the disruption to SHSs during the national response to the COVID-19 pandemic.

Background. Chronic obstructive pulmonary disease (COPD) is a debilitating lung condition characterised by progressive lung function limitation. COPD is an umbrella term and encompasses a spectrum of pathophysiologies including chronic bronchitis, small airways disease and emphysema. COPD caused an estimated 3 million deaths worldwide in 2016, and is estimated to be the third leading cause of death worldwide. The British Lung Foundation (BLF) estimates that the disease costs the NHS around £1.9 billion per year. COPD is therefore a significant public health challenge. This dataset explores the impact of hospitalisation in patients with COPD during the COVID pandemic.

PIONEER geography The West Midlands (WM) has a population of 5.9 million & includes a diverse ethnic & socio-economic mix. There is a higher than average percentage of minority ethnic groups. WM has a large number of elderly residents but is the youngest population in the UK. There are particularly high rates of physical inactivity, obesity, smoking & diabetes. The West Midlands has a high prevalence of COPD, reflecting the high rates of smoking and industrial exposure. Each day >100,000 people are treated in hospital, see their GP or are cared for by the NHS.

EHR. University Hospitals Birmingham NHS Foundation Trust (UHB) is one of the largest NHS Trusts in England, providing direct acute services & specialist care across four hospital sites, with 2.2 million patient episodes per year, 2750 beds & 100 ITU beds. UHB runs a fully electronic healthcare record (EHR) (PICS; Birmingham Systems), a shared primary & secondary care record (Your Care Connected) & a patient portal “My Health”.

Scope: All hospitalised patients admitted to UHB during the COVID-19 pandemic first wave, curated to focus on COPD. Longitudinal & individually linked, so that the preceding & subsequent health journey can be mapped & healthcare utilisation prior to & after admission understood. The dataset includes ICD-10 & SNOMED-CT codes pertaining to COPD and COPD exacerbations, as well as all co-morbid conditions. Serial, structured data pertaining to process of care (timings, staff grades, specialty review, wards), presenting complaint, all physiology readings (pulse, blood pressure, respiratory rate, oxygen saturations), all blood results, microbiology, all prescribed & administered treatments (fluids, nebulisers, antibiotics, inotropes, vasopressors, organ support), all outcomes. Linked images available (radiographs, CT).

Available supplementary data: More extensive data including wave 2 patients in non-OMOP form. Ambulance, 111, 999 data, synthetic data.

Available supplementary support: Analytics, Model build, validation & refinement; A.I.; Data partner support for ETL (extract, transform & load) process, Clinical expertise, Patient & end-user access, Purchaser access, Regulatory requirements, Data-driven trials, “fast screen” services.

Background. Coronavirus disease 2019 (COVID-19) was identified in January 2020. Currently, there have been more than 6 million cases & more than 1.5 million deaths worldwide. Some individuals experience severe manifestations of infection, including viral pneumonitis, adult respiratory distress syndrome (ARDS) & death. Many patients required ventilatory support including high flow oxygen, continuous positive airway pressure and intubated with or without tracheotomy. Different centres took different approaches to care delivery depending on ITU bed availability. This secondary care COVID OMOP dataset contains granular ventilatory, demographic, morbidity, serial acuity and outcome data in COVID-19.

PIONEER geography The West Midlands (WM) has a population of 5.9 million & includes a diverse ethnic & socio-economic mix. There is a higher than average percentage of minority ethnic groups. WM has a large number of elderly residents but is the youngest population in the UK. Each day >100,000 people are treated in hospital, see their GP or are cared for by the NHS. The West Midlands was one of the hardest hit regions for COVID admissions in both wave 1 & 2.

EHR. University Hospitals Birmingham NHS Foundation Trust (UHB) is one of the largest NHS Trusts in England, providing direct acute services & specialist care across four hospital sites, with 2.2 million patient episodes per year, 2750 beds & 100 ITU beds. ITU capacity increased to 250 beds during the COVID pandemic. UHB runs a fully electronic healthcare record (EHR) (PICS; Birmingham Systems), a shared primary & secondary care record (Your Care Connected) & a patient portal “My Health”. UHB has cared for >5000 COVID admissions to date. This data is in the OMOP format.

Scope: All COVID swab confirmed hospitalised patients to UHB from January – September 2020. The dataset includes highly granular patient demographics & co-morbidities taken from ICD-10 & SNOMED-CT codes. Serial, structured data pertaining to care process (timings, staff grades, specialty review, wards), severity, ventilatory requirements, acuity, all physiology readings (pulse, blood pressure, respiratory rate, oxygen saturations), all blood results, microbiology, all prescribed & administered treatments (fluids, antibiotics, inotropes, vasopressors, organ support), all outcomes.

Available supplementary data: More extensive data including wave 2 patients in non-OMOP form. Ambulance, 111, 999 data, synthetic data.

Available supplementary support: Analytics, Model build, validation & refinement; A.I.; Data partner support for ETL (extract, transform & load) process, Clinical expertise, Patient & end-user access, Purchaser access, Regulatory requirements, Data-driven trials, “fast screen” services.

The percentage of extra deaths that occurred due to winter, including those that had COVID-19 mentioned on the death certificate. The Excess Winter Mortality (EWM) index is calculated as the number of excess winter deaths divided by the average non-winter deaths, expressed as a percentage. Calculated so that comparisons can be made between sexes, age groups, and regions.

An EWM index of 20 shows that there were 20 percent more deaths in winter compared with the non-winter period. Provisional figures at country and region level are produced for the most recent winter using estimation methods, and so are rounded to the nearest 100 deaths. Data post 2019/20 should be treated with caution due to high numbers of deaths from COVID-19 in the summer period.

For data years 2020/21 onwards, instances where the number of winter deaths compared to non-winter deaths were equal to zero or a negative value, an EWM index is presented. (For earlier years, the EWM index was removed). A zero value for winter deaths compared to non-winter deaths is often affected by rounding, so in these instances, the winter mortality index can either be a positive or negative value. A negative winter mortality index means there were a higher number of deaths in the non-winter periods than the winter period.

Alternatively, figures are available for deaths excluding COVID-19, calculated using all-cause deaths that did not have COVID-19 mentioned on the death certificate.

Data is Powered by LG Inform Plus and automatically checked for new data on the 3rd of each month.

These data detail mask wearing behaviour in the COVID-19 pandemic in the UK. In total, we surveyed 18,805 adults across the UK over a period of 34 days, regarding their face covering behaviours. We performed an experiment where we showed respondents a media communication and assessed change in behavioural intentions related to masks and mask wearing

This study is part of ‘Between environmental concerns and compliance: How does media messaging affect motivation and choice between disposable versus reusable facemasks?’ (AH/W003813/1), funded by the Arts and Humanities Research Council. Some of the questions used in this survey were asked in another survey earlier in the COVID-19 pandemic (data entitled: UK Mask Wearing Behaviour and Attitudes in the COVID-19 Pandemic, Survey 1, 2022 available via related resources).

Facemasks are a crucial part of UK strategy to contain and mitigate transmission of COVID-19. While disposable facemasks present a convenient, low-cost solution, they carry greater associated environmental costs than reusable masks which are less likely to be discarded but require higher financial outlay. Although clearly central, the influence of media messaging - positive or negative - in determining people's mask-wearing choices is unknown, despite the considerable medical and environmental implications. This project will explore the complex factors underpinning consumer choice of masks and the adoption or rejection of facemask wearing, including responsible disposal of masks, by using multi-disciplinary methods to evaluate constructive and destructive messaging around (a) mask-wearing and motivation, and (b) sustainable choices within the facemask wearing arena. There are three components: 1. Assessing the influence and effectiveness of media messaging around the wearing of facemasks to date. 2. Examining the ways in which more effective media messaging can be developed to respond to rising rates of infection as well as potential long-term facemask use in the post-Covid era. 3. Examining how the wearing of facemasks can be encouraged in an environmentally friendly and sustainable manner to prevent short, medium and long-term collateral environmental harm, in alignment with the UK's obligations under international human rights and environmental laws. The overarching aim of this twelve-month project is, then, to better understand current facemask wearing behaviour as influenced by the media to improve uptake and enhance the effectiveness of media campaigns for the future, specifically considering environmental issues.

This is the estimated percentage of adults aged 16 and over in the local area who are inactive. These estimates include the activities of walking, cycling, dance, fitness and sporting activities, but exclude gardening which is outside of Sport England's remit. Office for Health Improvement and Disparities (OHID) publish physical activity data for adults aged 19+ that includes gardening. Activity is counted in moderate intensity equivalent minutes whereby each 'moderate' minute counts as one minute and each 'vigorous' minute counts as two moderate minutes. Depending on the number of minutes of moderate intensity equivalent (MIE) physical activity, people are described as being:

Inactive - Doing less than 30 minutes a week Fairly Active - Doing 30-149 minutes a week Active - Doing at least 150 minutes a week

Moderate activity is defined as where you raise your heart rate and feel a little out of breath. Vigorous activity is where you are breathing hard and fast and your heart rate has increased significantly (you will not be able to say more than a few words without pausing for breath). When making comparisons between figures, some differences seen may not be significant differences and so a degree of caution should be made before making conclusions. The survey was adapted during the COVID-19 pandemic. The survey sample is randomly selected from the Royal Mail’s Postal Address File ensuring a very high coverage of private residential addresses. The target sample size for each English local authority (excluding the City of London and Isles of Scilly) is 500 returns. Data may be suppressed for an area where the threshold of 30 is not reached. Population totals are created using Office for National Statistics (ONS) mid-year population estimates. Data is sourced from the adult Active Lives November to November survey.

Data is Powered by LG Inform Plus and automatically checked for new data on the 3rd of each month.

All infectious syphilis (primary, secondary and early latent) diagnoses among people accessing sexual health services* in England who are also residents in England, expressed as a rate per 100,000 population. Data is presented by area of patient residence and includes those residents in England and those with an unknown residence (data for those residents outside of England is not included).*Sexual health services providing STI related care (Levels 2 and 3). Further details on the levels of sexual healthcare provision are provided in the https://www.bashh.org/about-bashh/publications/standards-for-the-management-of-stis/ .RationaleSyphilis is an important public health issue in men who have sex with men (MSM) among whom incidence has increased over the past decade.Definition of numeratorThe number of infectious syphilis (primary, secondary and early latent) diagnoses among people accessing sexual health services in England who are also residents in England.Episode Activity codes (SNOMED or Sexual Health and HIV Activity Property Types (SHHAPT)) relating to diagnosis of infectious syphilis (primary, secondary and early latent) were used. The clinical criteria used to diagnose the conditions are given at https://www.bashh.org/guidelines .Data was de-duplicated to ensure that a patient received a diagnostic code only once for each episode. Patients cannot be tracked between clinics and therefore de-duplication relies on patient consultations at a single service.Definition of denominatorThe denominators for 2012 to 2022 are sourced from Office for National Statistics (ONS) population estimates based on the 2021 Census.Population estimates for 2023 were not available at the time of publication – therefore rates for 2023 are calculated using estimates from 2022 as a proxy.Further details on the ONS census are available from the https://www.ons.gov.uk/census .CaveatsEvery effort is made to ensure accuracy and completeness of GUMCAD data, including web-based reporting with integrated checks on data quality. However, responsibility for the accuracy and completeness of data lies with the reporting service.Data is updated on an annual basis due to clinic or laboratory resubmissions and improvements to data cleaning. Data may differ from previous publications.Figures reported in 2020 and 2021 are notably lower than previous years due to the disruption to SHSs during the national response to the COVID-19 pandemic.

All persons aged 13 to 14 years who have received the second (completing) dose of the HPV vaccine within each reporting area (local authority LA) as a percentage of all persons aged 13 to 14 years within each areaRationaleThe national human papillomavirus (HPV) immunisation programme was introduced in 2008 for secondary school year 8 females (12 to 13 years of age) to protect them against the main causes of cervical cancer. While it was initially a three dose vaccination programme, it was run as a two dose schedule from September 2014 following expert advice.The first HPV vaccine dose is usually offered to females in Year 8 (aged 12 to 13 years) and the second dose 12 months later in Year 9, but some local areas have scheduled the second dose from six months after the first. Therefore the completed course coverage is not available until the end of Year 9.From September 2019, 12 to 13 year old males became eligible for HPV immunisation alongside females, based on JCVI advice.Definition of numeratorNumber of persons in school year 9 (aged 13 to 14) who have received the second dose of HPV vaccine within each LA.Definition of denominatorNumber of year 9 (aged 13 to 14) persons in each LA.CaveatsOn 23 March 2020, all educational settings in England were advised to close by the UK Government as part of COVID19 pandemic measures. Although the importance of maintaining good vaccine uptake was impressed, operational delivery of all school aged immunisation programmes was paused for a short period of time as a consequence of school closures limiting access to venues for providers and children who were eligible for vaccination.The NHSEI central public health commissioning and operations team rapidly established an Immunisation Task and Finish Group, with regional NHSEI and PHE representation. The group was established to:assess the impact of COVID19 on all immunisation programmes, including school aged programmesdevelop technical guidance and a plan for restoration and recovery of school aged programmes, once education settings were re openedFrom 1 June 2020 some schools partially re-opened for some year groups for a mini summer term. NHSEI published clinical guidance for healthcare professionals on maintaining immunisation programmes during COVID19, and the Department of Education published further guidance which led to schools allowing vaccination sessions to resume on site. NHSEI commissioned, school aged immunisation providers were able to implement their restoration and recovery plans to commence catch up during the summer of 2020. This included delivery of programmes in school and community settings following a robust risk assessment and in line with UK government public health COVID19 guidance. The aim was to ensure that those eligible for HPV vaccination had been offered at least one dose of vaccine in line with JCVI recommendations with the second dose scheduled at a later date.In September 2020, schools across the UK reopened for general in person attendance. During the 2020 to 2021 academic year, students were required to stay at home and learn remotely if they tested positive for COVID 19 or if they were a contact of a confirmed COVID19 case and so school attendance rates in England were lower than normal, especially in areas with very high COVID19 incidence rates. In England, as part of a wider national lockdown in January 2021, schools were closed to all, except children of keyworkers and vulnerable children. From early March 2021, primary schools reopened, with a phased reopening of secondary schools.Although this led to some disruption of school-based immunisation programme delivery in the 2020 to 2021 academic year, NHSEI Regional Public Health Commissioning teams worked with NHSEI commissioned school aged immunisation providers to maintain the delivery of the routine programme and catch up. As the routine programme is commissioned for a school aged cohort rather than a school based cohort, providers were able to build on existing arrangements such as community based clinics in place for home school children. A wide variety of local arrangements were established to ensure programme delivery continued effectively and safely in the school and community premises, during the term time and school breaks.

This is the estimated percentage of adults aged 16 and over in the local area taking part in sport and physical activity at least twice in the last month. This is measured as the equivalent of 30 minutes or more activity at least twice in the last 28 days. Each session must last at least 10 minutes and be of at least moderate intensity. An individual can reach the minimum threshold by a combination of two 30-minutes sessions across the last 28 days or by six 10-minute sessions, for example. This is measured for all activities including sports, fitness, dance, cycling and walking (including for travel). Activities done by those aged 65 and over were assumed to be at least moderate in all cases. Moderate activity is defined as where you raise your heart rate and feel a little out of breath. Vigorous activity is where you are breathing hard and fast and your heart rate has increased significantly (you will not be able to say more than a few words without pausing for breath). When making comparisons between figures, some differences seen may not be significant differences and so a degree of caution should be made before making conclusions. The survey was adapted during the COVID-19 pandemic. The survey sample is randomly selected from the Royal Mail’s Postal Address File ensuring a very high coverage of private residential addresses. The target sample size for each English local authority (excluding the City of London and Isles of Scilly) is 500 returns. Data may be suppressed for an area where the threshold of 30 is not reached. Population totals are created using Office for National Statistics (ONS) mid-year population estimates. Data is sourced from the adult Active Lives November to November survey.

Data is Powered by LG Inform Plus and automatically checked for new data on the 3rd of each month.

All gonorrhoea diagnoses among people accessing sexual health services* in England who are also residents in England, expressed as a rate per 100,000 population. Data is presented by area of patient residence and include those residents in England and those with an unknown residence (data for those residents outside of England is not included).*Sexual health services providing STI related care (Levels 2 and 3). Further details on the levels of sexual healthcare provision are provided in the https://www.bashh.org/about-bashh/publications/standards-for-the-management-of-stis/ .RationaleGonorrhoea causes avoidable sexual and reproductive ill-health. Gonorrhoea is used as a marker for rates of unsafe sexual activity. This is because the majority of cases are diagnosed in sexual health clinics, and consequently the number of cases may be a measure of access to sexually transmitted infection (STI) treatment. Infections with gonorrhoea are also more likely than chlamydia to result in symptoms.Definition of numeratorThe number of gonorrhoea diagnoses among people accessing sexual health services in England who are also residents in England.Episode Activity codes (SNOMED or Sexual Health and HIV Activity Property Types (SHHAPT)) relating to diagnosis of gonorrhoea were used. The clinical criteria used to diagnose the conditions are given at https://www.bashh.org/guidelines .Data was de-duplicated to ensure that a patient received a diagnostic code only once for each episode. Patients cannot be tracked between services and therefore de-duplication relies on patient consultations at a single service.Definition of denominatorThe denominators for 2012 to 2022 are sourced from Office for National Statistics (ONS) population estimates based on the 2021 Census.Population estimates for 2023 were not available at the time of publication – therefore rates for 2023 are calculated using estimates from 2022 as a proxy.Further details on the ONS census are available from the https://www.ons.gov.uk/census .CaveatsEvery effort is made to ensure accuracy and completeness of GUMCAD data, including web-based reporting with integrated checks on data quality. However, responsibility for the accuracy and completeness of data lies with the reporting service.Data is updated on an annual basis due to clinic or laboratory resubmissions and improvements to data cleaning. Data may differ from previous publications.Figures reported in 2020 and 2021 are notably lower than previous years due to the disruption to SHSs during the national response to the COVID-19 pandemic.